J&J’s next COVID-19 vaccine challenge? Hurdling the ‘66%’ perception to win over a vaccine-hesitant public

With an FDA green light for emergency use, Johnson & Johnson’s COVID-19 shot now faces a communications hurdle. How will the company handle the comparisons with its vaccine rivals?

Already, there's wide and spreading chatter on social media and real-world word-of-mouth discussions about the J&J shot's 66% overall effectiveness rate. The company's response has been communication—and lots of it, with some help from its friend in public health.